Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer

作者全名："Zhou, Jie; Chen, Guanming; Wang, Jiuling; Zhou, Bo; Sun, Xuemin; Wang, Jinsong; Tang, Shu; Xing, Xiangju; Hu, Xiaofei; Zhao, Yang; Peng, Yu; Shi, Wenjiong; Zhao, Tingting; Wu, Yuzhang; Zhong, Hanbing; Hong, Ni; Ruan, Zhihua; Zhang, Yi; Jin, Wenfei"

作者地址："[Zhou, Jie; Wang, Jiuling; Sun, Xuemin; Wang, Jinsong; Shi, Wenjiong; Zhao, Tingting; Zhang, Yi] Chongqing Int Inst Immunol, Chongqing 400030, Peoples R China; [Zhou, Jie; Zhao, Yang; Peng, Yu; Ruan, Zhihua] Army Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China; [Chen, Guanming; Zhou, Bo; Zhong, Hanbing; Hong, Ni; Jin, Wenfei] Southern Univ Sci & Technol, Sch Life Sci, Shenzhen 518055, Peoples R China; [Wang, Jiuling; Sun, Xuemin; Wang, Jinsong; Wu, Yuzhang] Army Med Univ, Inst Immunol, PLA, Chongqing 400038, Peoples R China; [Tang, Shu] Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing 400038, Peoples R China; [Xing, Xiangju] Chongqing Med Univ, Pulm & Crit Care Med, Affiliated Hosp 3, Chongqing 400038, Peoples R China; [Hu, Xiaofei] Army Med Univ, Southwest Hosp, Dept Radiol, Chongqing 400038, Peoples R China; [Zhao, Tingting; Zhang, Yi] Chongqing Univ Technol, Sch Pharm & Bioengn, Chongqing 400054, Peoples R China"

通信作者："Zhang, Y (通讯作者)，Chongqing Int Inst Immunol, Chongqing 400030, Peoples R China.; Ruan, ZH (通讯作者)，Army Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.; Jin, WF (通讯作者)，Southern Univ Sci & Technol, Sch Life Sci, Shenzhen 518055, Peoples R China.; Zhang, Y (通讯作者)，Chongqing Univ Technol, Sch Pharm & Bioengn, Chongqing 400054, Peoples R China."

来源：ONCOGENESIS

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000976332000001

JCR分区：Q1

影响因子：6.2

年份：2023

卷号：12

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：　

摘要："Anti-PD-1 therapy has shown promising outcomes in the treatment of different types of cancer. It is of fundamental interest to analyze the efficacy of anti-PD-1 therapy in cancer patients infected with hepatitis B virus (HBV) since the comorbidity of HBV and cancer is widely documented. We designed a multicenter retrospective study to evaluate the efficacy of anti-PD-1 therapy on non-liver cancer patients infected with HBV. We found anti-PD-1 therapy achieved much better outcomes in HBV+ non-liver cancer patients than their HBV- counterparts. We performed single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from esophageal squamous cell carcinoma (ESCC) patients. We found both cytotoxicity score of T cells and MHC score of B cells significantly increased after anti-PD-1 therapy in HBV+ ESCC patients. We also identified CX3CR1(high) T-EFF, a subset of CD8(+) T-EFF, associated with better clinical outcome in HBV+ ESCC patients. Lastly, we found CD8(+) T-EFF from HBV+ ESCC patients showing higher fraction of Exhaustion(hi) T than their HBV- counterpart. In summary, anti-PD-1 therapy on HBV+ non-liver cancer patients is safe and achieves better outcomes than that on HBV- non-liver cancer patients, potentially because HBV+ patients had higher fraction of Exhaustion(hi) T, which made them more efficiently respond to anti-PD-1 therapy."

基金机构："Chongqing International Institute for Immunology [2020YJC08]; National Key R&D Program of China [2021YFF1200900]; National Natural Science Foundation of China [81802783]; Guangdong Basic and Applied Basic Research Foundation [2023A1515011908]; Shenzhen Innovation Committee of Science and Technology [JCYJ20220818100401003, JCYJ20180504170158430]; Shenzhen Science and Technology Program [KQTD20180411143432337]; Natural Science Foundation of Chongqing Science & Technology Commission [CSTB2022NSCQ-MSX0220]"

基金资助正文："This study was supported by Chongqing International Institute for Immunology(2020YJC08), National Key R&D Program of China (2021YFF1200900), National Natural Science Foundation of China (81802783), Guangdong Basic and Applied Basic Research Foundation (2023A1515011908), Shenzhen Innovation Committee of Science and Technology (JCYJ20220818100401003, JCYJ20180504170158430),Shenzhen Science and Technology Program (KQTD20180411143432337), Natural Science Foundation of Chongqing Science & Technology Commission(CSTB2022NSCQ-MSX0220)."